【摘要】 钙敏感受体是治疗终末期肾病继发性甲状旁腺功能亢进(SHPT)的重要靶点。Etelcalcetide是一种新研发的注射用拟钙剂,本文将对其治疗血液透析患者SHPT的疗效、不良反应、药理学特性及远期预后进行综合分析。本文通过检索国内外开展的有关Etelcalcetide的临床试验及动物试验研究资料,进行整理分析后发现,Etelcalcetide可以显著降低血液透析患者的血清甲状旁腺激素(PTH),并同时降低成纤维细胞生长因子23(FGF-23)、血清钙等指标,但在患者心血管事件、死亡率、骨折、血管钙化等远期预后等方面仍然缺乏证据。常见的药物相关不良反应包括无症状低钙血症、呕吐、恶心、有症状性低钙血症,静脉注射给药途径并未明显减少胃肠道不良反应。综上所述,Etelcalcetide可用于治疗成人血液透析患者SHPT,但其对于病患的远期预后仍需进一步研究。更多还原

【Abstract】 Calcium sensitive receptor is an important target for treating secondary hyperparathyroidism(SHPT) of end-stage renal diseases. Etelcalcetide is a novel injectable calcimimetic agent, and in this article a comprehensive analysis was performed for its efficacy, adverse reactions, pharmacological properties and expected prognosis for the treatment of SHPT in hemodialysis patients. After retrieving and analyzing the data of clinical trials and animal experiments of Etekalcetide uhich carried out home and abrood,we fourd that, Etelcalcetide could significantly reduce the serum parathyroid hormone(PTH) in hemodialysis patients, and the indexes of fibroblast growth factor 23(FGF-23) and serum calcium. However, there is still less evidence for long-term prognosis indices such as cardiovascular events, mortality, fractures and vascular calcification. Common drug-associated adverse reactions include asymptomatic hypocalcemia, vomiting, nausea, symptomatic hypocalcemia, and intravenous injection is unlikely to mitigate the gastrointestinal adverse effects. In conclusion, Etelcalcetide can be used to treat secondary hyperthyroidism in adult hemodialysis patients. However, the long-term prognosis of the patients should be further investigated.更多还原